The Chapman Lab focuses on modulating B lymphocytes—key adaptive immune cells responsible for antibody production—to improve outcomes in both infectious disease and autoimmunity.
Advancing Immunity
Innovations in
B Lymphocyte Modulation
Antigen and Immunotherapy Engineering
Engineering B cells to boost immunity in infections and suppress autoimmunity through targeted therapies.
B cell Modulation using Targeted Therapeutics
Employing targeted therapies to boost vaccine-induced immunity and suppress autoimmunity by eliminating autoreactive B cells.
Germinal Center Biology
Investigating the molecular mechanisms driving humoral and autoimmunity
ABOUT
Advancing B Cell Therapeutics
Launching January 2026 at Vanderbilt University
Focused on cutting-edge therapeutic development
Supportive, rigorous, and exciting research environment
Seeking driven students, postdocs, and technicians
Apply now via our online contact form
Opportunities
Join the Team
The Chapman Lab opens January 2026 in Vanderbilt’s Department of Chemical and Biomolecular Engineering. We’re looking for enthusiastic, driven individuals excited to develop next-generation B cell therapeutics. Current openings include positions for lab technicians, graduate students, and postdoctoral researchers.
